印度一项单中心研究中套细胞淋巴瘤的临床病理研究

A clinicopathologic study of mantle cell lymphoma in a single center study in India.

作者信息

Gujral S, Agarwal A, Gota V, Nair R, Gupta S, Pai S K, Sanger M, Shet T, Subramanian P G, Muckaden M, Laskar S

机构信息

Department of Pathology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.

出版信息

Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):315-22. doi: 10.4103/0377-4929.42503.

DOI:10.4103/0377-4929.42503

PMID:18723950

Abstract

We present clinical features, histopathology and results of treatment in cases of mantle cell lymphoma (MCL) at our hospital. We had 93 cases (2.1%) of MCL out of total 4301 cases of non-Hodgkin's lymphoma (NHL) in a 4-year period. It included 68 cases (1.7%) of MCL from 3987 cases of NHL diagnosed on histopathology. Remaining 25 cases (7.9%) diagnosed solely on peripheral blood examination were excluded. Thirty-six (85%) patients had advanced-stage disease. Sixty-three were nodal and five were extranodal (all gastrointestinal tract). Common patterns were diffuse (64%), nodular (25%) and mantle zone type (11%). Sixty-two cases had lymphocytic while six had blastic morphology (all nodal). Tumor cells expressed CD20 (100%), CD43 (94%), CD5 (89%) and cyclin D1 (85%). Bone marrow was involved in 25 (59%) cases. Thirty-two patients could be treated. Median recurrence-free survival was 22.23 months. Diffuse pattern of nodal involvement had a lower overall survival.

摘要

我们展示了我院套细胞淋巴瘤（MCL）病例的临床特征、组织病理学及治疗结果。在4年期间，我们从4301例非霍奇金淋巴瘤（NHL）病例中确诊了93例（2.1%）MCL。其中包括从3987例经组织病理学确诊的NHL病例中诊断出的68例（1.7%）MCL。其余仅通过外周血检查诊断出的25例（7.9%）被排除。36例（85%）患者处于晚期。63例为淋巴结受累，5例为结外受累（均为胃肠道）。常见模式为弥漫型（64%）、结节型（25%）和套区型（11%）。62例具有淋巴细胞形态，6例具有母细胞形态（均为淋巴结受累）。肿瘤细胞表达CD20（100%）、CD43（94%）、CD5（89%）和细胞周期蛋白D1（85%）。25例（59%）病例有骨髓受累。32例患者可接受治疗。无复发生存期的中位数为22.23个月。淋巴结受累的弥漫型总体生存率较低。